Deal Buzz: Is Abbott Teaming Up With India’s Biocon To Develop Nutrition Products?
This article was originally published in PharmAsia News
India-based Biocon’s CRO arm Syngene is said to be partnering with Abbott over nutrition products, but neither company will provide details…yet.
You may also be interested in...
MUMBAI - French drug maker Sanofi's long search for high-growth OTC brands in India finally materialized as it announced the acquisition of Mumbai-headquartered Universal Medicare Pvt. Ltd.'s nutraceutical businesses
Abbott Established Products Senior VP Michael Warmuth Stresses Diversified Portfolio In Emerging Markets: An Interview With PharmAsia News (Part 1 of 2)
Michael Warmuth, senior vice president, Established Products Division, Abbott Laboratories handles emerging markets, one of the most ambitious growth areas for his company. Among the EMs, India stands as a sharp focus market for Abbott, demonstrated last year by its acquisition of Piramal Healthcare Ltd.'s prescriptions business for $3.72 billion. Warmuth says India is on top of his priority list and though critics may question the high price that Abbott paid for the Piramal business, there is a large potential to tap the "incredibly high unmet medical need."
HYDERABAD, India - After several months of discussions, debt-laden Indian drug maker Wockhardt Ltd. finally managed to sell its growing nutritional business to French food giant Group Danone for reportedly $354 million - a quantum jump from the $130 million that Abbott Laboratories Ltd. had agreed to pay for the same assets exactly two years ago